Bristol-Myers Squibb and Roche Enter into a Clinical Collaboration Agreement to Conduct Combination Studies with YERVOY and Vemurafenib

Bristol-Myers Squibb Company BMY announced today it has entered in to a clinical collaboration agreement with Roche (RHHBY) to evaluate the utility of Bristol-Myers Squibb's CTLA-4 inhibitor, YERVOY, in combination with Roche's investigational oral BRAF inhibitor, vemurafenib, in treating patients with a specific type of metastatic melanoma.